S5059Referred to Committee

A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-07-21
Introduced
3
Cosponsors
S
ⓘ
Type

Sponsor

Ashley Moody
Ashley Moody
Republican · FL · Senator
Votes with party: 76.0% (896 recorded votes)
Top industries funding sponsor:
  • Conservative Groups$11,211k
  • Progressive Groups$1,500k

Full profile: /officials/M001244

Source: Congress.gov · FEC

Cosponsors (3)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

2026-07-21

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

The bill would speed up the government's approval process for biosimilar drugs, which are lower-cost versions of expensive biologic medications that work similarly to the originals. This change would help patients and insurance companies access more affordable treatment options more quickly, while giving pharmaceutical companies a clearer pathway to bring these alternative drugs to market.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 5059 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 5059 To amend the Public Health Service Act to streamline the review of biosimilar biological products. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES July 21, 2026 Mrs. Moody (for herself, Ms. Alsobrooks, Mr. Scott of Florida, and Ms. Blunt Rochester) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To amend the Public Health Service Act to streamline the review of biosimilar biological products. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. STREAMLINING BIOSIMILAR REVIEWS. Section 351(k)(5) of the Public Health Service Act (42 U.S.C. 262(k)(5)) is amended-- (1) by striking subparagraph (B); and (2) by redesignating subparagraph (C) as subparagraph (B). <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.